Pharma Industry

The firm ran into trouble after the US FDA informed it of 55 cases of adverse events on the use of its eye drops, some of which caused permanent loss of vision and at least one caused death

Domestic pharmaceutical industry is expected to witness a revenue growth of 6-8 per cent in the next fiscal, rating agency Icra said on Thursday. Despite several disruptive events, the Indian pharmaceutical market (IPM) witnessed a healthy CAGR of 10.9 per cent between FY2012 and FY2022. "Going forward, ICRA expects revenues for its sample set to increase by 6-8 per cent in FY2024 against 3-4 per cent growth in FY2023," Icra Assistant Vice President & Sector Head - Corporate Ratings Mythri Macherla said in a statement. Structural factors such as ageing population and continued rise in lifestyle/chronic diseases, in addition to WPI-linked price hikes for NLEM products, new product introductions, and annual price hikes for non-NLEM products, are expected to support revenue growth for the industry, she added. Since FY2018, IPM growth has largely been supported by price increases and new product introductions, even as volume growth remained between 2-3 per cent each fiscal, Macherla ..

Consumer companies like Godrej and Dabur too have significant exposure to Nigeria

Govt should not solely depend on monetary incentives

Sources say refunds of 600 entities not being processed

According to the ministry, chemical ethylene glycol was found in a batch of syrup during laboratory tests

Noida-based Marion Biotech's Dok-1 Max anti-cold medicine under scanner after the Central Asian nation blames it for 18 deaths

High raw material prices to put pressure on margins

Reinvent and innovate will be the key mantra for the Indian pharma industry in the New Year as the 'pharmacy of the world' looks to move from volume to value leadership

Companies will have to manage work to match India's National List of Essential Medicines but it will be worth the endeavour, she says

Fosun Pharma, a listed arm of Chinese conglomerate Fosun International Ltd., has been working with an adviser as it informally gauges interest in its controlling stake in Gland, the people said

Will fund transaction from internal accruals

Experts say this will create a predictable pricing regime for both the consumer and manufacturer

The UCPMP is voluntary and there is no legal penalty for violating the code

In a Q&A, the firm's US business head and its group CFO talk about their plans to scale the specialty products business further, and dwell on the company's strategies post-pandemic

Excluding the strong US show led by Revlimid, Q2 was a mixed bag

India will not impose anti-dumping duty on a Chinese chemical used in pharma industry as the finance ministry has not accepted the recommendations of DGTR for imposing the levy. The commerce ministry's investigation arm DGTR had conducted a probe into the alleged dumping of "(4R-Cis)-1-1-Dimethylethyl-6-cyanomethyl-2, 2-dimethyl-1, 3-dioxane-4-acetate" from China, and in August it recommended the imposition of the duty. "The central government, after considering the final findings of the designated authority (DGTR), has decided not to accept the ... recommendations," a memorandum of Department of Revenue said. While Directorate General of Trade Remedies (DGTR) recommends the duty, Department of Revenue takes the final decision to impose it. This chemical is also known as ATS-8, which is a key raw material for manufacturing Atorvastatin active pharmaceutical ingredient. In international trade parlance, dumping happens when a country or a firm exports an item at a price lower than

Pharma industry insiders claimed that most contamination-related problems arise due to solvents

Sales declining anyway and there is no need to ban because of alleged misuse, say experts

The industry is divided on the issue of phasing out codeine-based cough syrups, which are used by many as intoxicants